Insights

Clinuvel (ASX:CUV) share price down despite recording 10th consecutive net profit

Clinuvel Pharmaceuticals Limited (ASX: CUV) announced its tenth consecutive half-year profit today.  Despite this news, at the time of writing, the Cinuvel share price was down 0.6% to $19.92. We take a closer look at the announcement and what this means for the Clinuvel share price. Clinuvel records tenth consecutive half-year profit Clinuvel Pharmaceuticals released
The post Clinuvel (ASX:CUV) share price down despite recording 10th consecutive net profit appeared first on The Motley Fool Australia. –

Red and white arrows showing share price drop

Clinuvel Pharmaceuticals Limited (ASX: CUV) announced its tenth consecutive half-year profit today.  Despite this news, at the time of writing, the Cinuvel share price was down 0.6% to $19.92.

We take a closer look at the announcement and what this means for the Clinuvel share price.

Clinuvel records tenth consecutive half-year profit

Clinuvel Pharmaceuticals released its half-yearly report earlier today.

The company’s report highlighted Clinuvel recording its tenth consecutive half-year profit. For the 6 months ending 31 December, Clinuvel saw net profit after tax (NPAT) soar 962%. Leading to a record $6.5 million.

The company also reported improved revenue for the half-year of $15.743 million, 58% higher from the prior corresponding period.

For the first-half of FY21, Clinuvel also saw positive earnings per share of 13.3 cents per share. This marked a 956% increase from the same period last year.

In addition, the company noted a strong balance sheet with no debt and $78 million in cash. Despite the strong equity position, Clinuvel did not declare an interim dividend.

Chief financial officer, Darren Kenny, noted that “The company is in a sound financial position to continue to grow and fund its expansion. We are investing in our R&D and clinical programs and progressing our evolution into a diversified pharmaceutical company”.

What fuelled the record profit?

Despite global economic uncertainty under the COVID-19 pandemic, Clinuvel recorded strong commercial sales for the first half of FY21.

On a constant currency basis, Clinuvel recorded an 87% increase in revenue from the distribution of its flagship SCENESSE product. The company attributed the lift to commercial sales in the US, earlier ordering, and new patients.

Clinuvel’s management also cited the company’s efficient business model for the strong half-year result.

The company also highlighted additional clinical development plans for SCENESSE, with 2 new clinical programs. The expansion follows the company’s recent announcement earlier this month, which saw SCENESSE added to the Israeli ‘National Health Basket’ (NHB).

How has the Clinuvel share price responded?

Clinuvel is a global biopharmaceuticals company that develops drugs designed for the treatment of severe genetic and developmental skin disorders. The company’s flagship Scenesse drug is designed to prevent phototoxicity in patients with erythropoietic protoporphyria (EPP). 

The Clinuvel share price was trading around 4% higher today, hitting an intra-day high of $20.88.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Clinuvel (ASX:CUV) share price down despite recording 10th consecutive net profit appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!